Accelerated cellular rejection with prominent interstitial hemorrhage following cemiplimab treatment: How can we approach a renal transplant recipient under anti-PD1 therapy?

The development of immune checkpoints from which tumor cells escape has revolutionized oncology in the past decade. However, its use is not indicated for solid organ transplant (SOT) recipients who...